Follow
Ronan Kelly
Ronan Kelly
Director of Oncology Baylor University Medical Center
Verified email at BSWHealth.org
Title
Cited by
Cited by
Year
Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer
RJ Kelly, JA Ajani, J Kuzdzal, T Zander, E Van Cutsem, G Piessen, ...
New England Journal of Medicine 384 (13), 1191-1203, 2021
9972021
Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study
H Gacaferi, GS Collaborative, COVIDSurg Collaborative
Anaesthesia 76 (6), 2021
528*2021
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
D Planchard, TM Kim, J Mazieres, E Quoix, G Riely, F Barlesi, PJ Souquet, ...
The Lancet Oncology 17 (5), 642-650, 2016
4602016
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
ED Thompson, M Zahurak, A Murphy, T Cornish, N Cuka, E Abdelfatah, ...
Gut 66 (5), 794-801, 2017
4392017
Pneumonitis in non–small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors
K Suresh, KR Voong, B Shankar, PM Forde, DS Ettinger, KA Marrone, ...
Journal of Thoracic Oncology 13 (12), 1930-1939, 2018
3432018
Scientific advances in lung cancer 2015
AS Tsao, GV Scagliotti, PA Bunn Jr, DP Carbone, GW Warren, C Bai, ...
Journal of Thoracic Oncology 11 (5), 613-638, 2016
3292016
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial
A Lopez-Chavez, A Thomas, A Rajan, M Raffeld, B Morrow, R Kelly, ...
Journal of clinical oncology 33 (9), 1000, 2015
2472015
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers
R Hassan, SJ Cohen, M Phillips, I Pastan, E Sharon, RJ Kelly, ...
Clinical cancer research 16 (24), 6132-6138, 2010
2362010
Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin
RJ Kelly, A Lopez-Chavez, D Citrin, JE Janik, JC Morris
Molecular cancer 10, 1-11, 2011
2182011
Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection
PA McCullough, RJ Kelly, G Ruocco, E Lerma, J Tumlin, KR Wheelan, ...
The American journal of medicine 134 (1), 16-22, 2021
2092021
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors
G Giaccone, A Rajan, A Berman, RJ Kelly, E Szabo, A Lopez-Chavez, ...
Journal of Clinical Oncology 29 (15), 2052, 2011
2062011
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer
RJ Kelly, D Draper, CC Chen, RW Robey, WD Figg, RL Piekarz, X Chen, ...
Clinical Cancer Research 17 (3), 569-580, 2011
2022011
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors
A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, ...
Clinical cancer research 18 (8), 2344-2351, 2012
1882012
Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011
YCT Shih, F Smieliauskas, DM Geynisman, RJ Kelly, TJ Smith
Journal of Clinical Oncology 33 (19), 2190, 2015
1752015
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer
RJ Kelly, A Thomas, A Rajan, G Chun, A Lopez-Chavez, E Szabo, ...
Annals of oncology 24 (10), 2601-2606, 2013
1642013
Thymic malignancies: from clinical management to targeted therapies
RJ Kelly, I Petrini, A Rajan, Y Wang, G Giaccone
Journal of clinical oncology 29 (36), 4820, 2011
1612011
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): A single-arm, phase 1b–2 trial
DVT Catenacci, YK Kang, H Park, HE Uronis, KW Lee, MCH Ng, ...
The lancet oncology 21 (8), 1066-1076, 2020
1582020
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas
A Rajan, RJ Kelly, JB Trepel, YS Kim, SV Alarcon, S Kummar, M Gutierrez, ...
Clinical Cancer Research 17 (21), 6831-6839, 2011
1442011
Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy
K Suresh, KJ Psoter, KR Voong, B Shankar, PM Forde, DS Ettinger, ...
Journal of Thoracic Oncology 14 (3), 494-502, 2019
1322019
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
K Suresh, J Naidoo, Q Zhong, Y Xiong, J Mammen, MV De Flores, ...
The Journal of clinical investigation 129 (10), 4305-4315, 2019
1272019
The system can't perform the operation now. Try again later.
Articles 1–20